Loading stock data…
$8.54-0.27 (-3.05%)
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Korro Bio, Inc. in the Healthcare sector is trading at $8.54 with a market capitalization of $204M. Wall Street consensus targets $20.20 (10 analysts), implying a +136.5% move over the next 12 months. The stock is currently near its 52-week low of $5.20, remaining 27.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $1.29M↑ | $1.09M↓ | $1.46M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$20.11M↑ | -$20.44M↓ | -$15.88M↑ | -$19.24M↑ | -$25.97M |
| Net Income | -$18.92M↑ | -$19.63M↑ | -$50.04M↓ | -$18.06M↑ | -$25.77M |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead produ...